Voriconazole as Prophylactic Therapy in Lung Transplant Recipients (VORI)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00455364
(Protocol never received funding.)
The purpose of this study is to compare the safety and efficacy of Voriconazole with Itraconazole following lung transplantation.
Condition or disease
All participants will receive itraconazole during their inpatient post transplant stay. As an outpatient, ten subjects will be randomized to receive itraconazole 200mg orally once daily for 6 month and ten patients to receive voriconazole 200mg orally twice daily for 6 months . All subjects will be followed in the clinic as per the standard transplant treatment
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 65 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Bilateral-lung or single-lung transplant recipients between the ages of 18- 65 years old.
Patients must be able to give informed consent prior to and again after transplantation
Lung transplant patients unable to give informed consent.
Prior adverse reaction to the drug itraconazole or voriconazole